Skip to main content
. 2022 May 4;23(9):5105. doi: 10.3390/ijms23095105

Figure 5.

Figure 5

Effect of acetylsalicylic acid on non-amenable variants. IF-GLA-MUTs, specifically IF-GLA-A230T (A) and IF-GLA-E341D (B), were treated for 72 h with the following drugs: i. untreated; ii. 10 μM DGJ; iii. 4 mM acetylsalicylic acid (ASA); iv. 10 μM DGJ + 4 mM ASA. AGAL specific activity measured on protein extracts is shown. Tukey’s HSD was used to evaluate significative differences among treatments (***: p < 0.001; **: p < 0.01; *: p < 0.05; n = 2). As expected, the combined treatment did not increase the enzymatic activity of non-amenable variants. Immunoblots showed the increase of the AGAL precursor as a result of the acetylsalicylic acid treatment (U = untreated; D = DGJ 10 μM; A = ASA 4 mM; D + A = DGJ 10 μM + ASA 4 mM). Each panel includes specific activity and an immunoblot for a cell line.